Introduction
Apoptosis, a programmed cell suicide mechanism, is an important physiological phenomenon in developmental processes as well as in homeostatic processes, especially in the elimination of intruders and cancer cells. The cell death machinery can be activated by a variety of distinct signals that converge into conserved common pathways involving proteolytic enzymes (caspases; Shi, 2002) as well as regulatory proteins of the Bcl-2 family (Adams and Cory, 1998; Gross et al., 1999) .
Disruption of this machinery may contribute to the development of cancer, autoimmune or degenerative diseases (Cory, 1995; Thompson, 1995) . The development of malignant tumours results either from deregulated proliferation or from an inability of cells to undergo apoptotic cell death (Steller, 1995) . The latter can be the consequence of overexpression of antiapoptotic proteins (e.g. Bcl-2) or by silencing/mutation of proapoptotic genes (e.g. TMS1). Early induction of apoptosis of tumour cells is the preferred treatment option for human cancers. Slowly growing but viable tumour cells, recovering from nonapoptotic damage, were proposed to be an overlooked factor in the therapeutic failure of many cancer treatments (Woynarowska and Woynarowski, 2002 ). Therefore, a major goal is to identify factors that specifically induce apoptosis in cancer cells but not in normal tissue.
Recently in this journal, Li et al. (2001) reported the cloning of a presumed new type of apoptosis-inducing gene named ASY. The ASY protein is identical to the previously described Nogo-B/RTN4-B1, one of three major splice variants of the fourth member of the reticulon family, already cloned some years ago (Nagase et al., 1998; Morris et al., 1999; Chen et al., 2000) . The longer splice form of the nogo/rtn4 gene, Nogo-A, has been described as a potent inhibitory protein for neurite outgrowth (Chen et al., 2000) .
Based mainly on transfection experiments, it was claimed that Nogo-B specifically induces apoptosis in cancer cells. In addition, it has been shown by in situ hybridization that Nogo mRNA was absent in small cell lung cancer (SCLC; Li et al., 2001) . These findings would open new possibilities for gene therapeutic approaches in the treatment of cancer.
In the present study, we tested this hypothesis by investigating the effects of stable Nogo-B overexpression on the cellular proliferation rate and on the cells' sensitivity to exposure to proapoptotic stimuli.
Results

Nogo-B is expressed in a variety of carcinomas and cancer cells
Absence or downregulation of the presumed proapoptotic protein Nogo-B could be a crucial element in the generation of cancer (Li et al., 2001) . To analyse if the suppression of Nogo-B mRNA is a general finding in transformed cells, we screened public databases for Nogo-B-specific ESTs and their tissues of origin. Nogo-B mRNA is present in a variety of carcinomas: 50% of the documented Nogo-B-specific dbESTs are derived from tumorigenic tissues, for example, breast cell/ mammary tumours (Genbank Accession numbers BI691132, BI157842), osteosarcoma (Accession BG109465), lung tumour (Accession BI152683) and several neuroblastoma cell lines (SK-N-SH, SH-SY5Y, Paju, B104, PC12; Oertle et al., 2003) . Nogo-A, which shares the C-terminal 'proapoptotic' domain (Li et al., 2001) with Nogo-B, is also present in different tumours (e.g. glioblastoma, anaplastic oligodendroglioma, pilocytic astrocytoma; Michel et al., 1999; and Accession BG819566, BG222516, AI498155 and AI498805) .
These findings show that the absence of Nogo-B is not a common feature in tumorigenic tissues.
Nogo-B mRNA and protein are expressed endogenously in SaOS-2 osteosarcoma and CHO cells Proapoptotic effects of Nogo-B have been observed, for example, by transient transfection into the osteosarcoma-derived SaOS-2 cell line (Li et al., 2001) . However, it was not investigated if these tumorigenic cell lines lack endogenous Nogo-B expression. We therefore analysed SaOS-2 cells for endogenous expression of the different Nogo splice variants (Figure 1 ). RT-PCR and Western blot clearly demonstrate the presence of endogenous Nogo-B (Figure 1a, b) . Immunocytochemistry ( Figure 1c ) revealed a typical subcellular localization of endogenous Nogo-B protein in an ER-like pattern in SaOS-2 cells, as has been widely described for other reticulon proteins (Senden et al., 1994; van de Velde et al., 1994a; Morris et al., 1999) . To analyse if there are any differences in the 'proapoptotic' domain of Nogo-B expressed by SaOS-2 cells because of mutations of the nogo gene, we cloned a 0.8 kb fragment of the Nogo-B transcript comprising the 'proapoptotic' domain in the C-terminus. No nucleotide sequence alterations were detected (100% match to current Genbank sequences).
These results show that SaOS-2 cells, despite being tumorigenic, express Nogo-B endogenously at a considerable level.
Nogo-B can be overexpressed in SaOS-2 and CHO cells by stable transfection
In order to study the effect of overexpressed ectopic Nogo-B, we transfected SaOS-2 and CHO cells with a myc-tagged rat Nogo-B expression plasmid and successfully selected for stable transfectants with G418. In Figure 2 , SaOS-2 cell lines overexpressing Nogo-B at different levels are shown by immunocytochemistry and Western blotting with an anti-myc monoclonal antibody (Figure 2a, b) . Western blots with an anti-Nogo antiserum demonstrate that the strong expressing SaOS-2 cell lines have a more than twofold overexpression compared to endogenous Nogo-B (Figure 2c ). The clear-cut overexpression of Nogo-B in these cells did not lead to apoptosis. Similarly, stable CHO transfectants show strong overexpression of ectopic Nogo-B (Figure 2d ). Bcl-2 levels in SaOS-2 wild-type and Nogo-B-overexpressing cell lines do not differ, but are considerably lower compared to the levels in neuroblastoma cell lines SH-SY5Y and SK-N-SH (Figure 2e ).
These results are in clear contradiction to what has been previously reported, namely that stable Nogo-B transfectants in SaOS-2 and CGL4 cells were not obtainable (Li et al., 2001 ).
Nogo-B-overexpressing cell lines do not differ from wild types in their proliferation rate
To study if stable transfection of Nogo-B does lead to a change of the growth properties of cells, we analysed the proliferation rate of SaOS-2 wild-type cells and a stable lacZ-transfected cell line in comparison to two stable SaOS-2 cell lines (C8 and D11) (Figure 3a, b) . The average duplication rate of SaOS-2 cells is B50 h (Figure 3b ).
To investigate if Nogo-B has an influence on the growth rate of nontumorigenic cell lines, we compared CHO cells stably transfected with Nogo-B to wild-type CHO cells as well as CHO cells stably transfected with Nogo-A, RTN1-A or RTN3, respectively (Figure 2d ). Neither Nogo-B nor any of the other RTN-membertransfected CHO cell lines displayed significantly different growth behaviour (Figure 3c) , with average duplication rates of B12 h (Figure 3c ).
This result demonstrates that stably transfected Nogo-B cells do not significantly change their cellular proliferation pace. These findings illustrate that Nogo-B does not increase the sensitivity of SaOS-2 cells to apoptotic stimuli like staurosporine or tunicamycin. In CHO cells, both RTN1-A and Nogo-B reduce significantly the degree of apoptosis upon tunicamycin treatment.
The second hydrophobic region of Nogo-B is responsible for the ER-membrane association
The proapoptotic properties of Nogo-B have been attributed to the second putative transmembrane region in the C-terminal RTN domain by transient transfections of Nogo-B deletion mutants (Li et al., 2001 ). This would imply that all known Nogo isoforms should share this same biological effect. We therefore constructed a Nogo-B mutant lacking part of the C-terminal RTN domain ('ASY-TTL'; Li et al., 2001) and looked for subcellular localization by transfection in COS-7 and Proliferation rates of SaOS-2 cell lines from day 1 to 3 (GR1-3), day 3 to 5 (GR3-5) and day 5 to 7 (GR5-7). The growth rate is dependent on the cell density and is therefore decreased for GR5-7. The duplication rate is B50 h. (c) Proliferation rates of CHO cell lines from day 1 to 2 (GR1-2), day 2 to 3 (GR2-3) and day 3 to 4 (GR3-4). The duplication rate is B12 h. The means7s.e. are represented. ANOVA for repeated measurements showed no statistical difference between the groups for SaOS-2 cells SaOS-2 cells. While strongly overexpressed, full-length Nogo-B always localizes to ER and Golgi membranes (Figure 5a ), eventually leading to the distension of cisternae of the endoplasmic reticulum (Figure 2a) . ASY-TTL, in contrast, could be detected in ER membranes only at relatively low expression levels. The protein was mainly localized in the cytoplasm in heavily overexpressing cells (Figure 5b ). Cell fractionation experiments confirmed the change in subcellular localization: Nogo-B was found in the microsomal fraction, while ASY-TTL was detected both in the cytoplasmic and in the microsomal fraction (Figure 5c ). The different subcellular localization of ASY-TTL is not because of the absence of the ER-membrane retention signal (KRKAE) in the C-terminus (van der Haar, unpublished). These findings show that the ER-membrane association of the Nogo proteins is crucially dependent on the presence of the second hydrophobic region. Mutations that change the subcellular localization of Nogo-B could well have important indirect effects on the physiological roles of the protein.
Discussion
In this study, we demonstrate that Nogo-B is expressed in a variety of carcinomas and cancer cells and that, in contrast to earlier reports, stable Nogo-B-transfected SaOS-2 cells can be obtained. These cell lines do not differ in their proliferation rates, or in their sensitivity to proapoptotic stimuli like staurosporine or tunicamycin. Deletion of the second hydrophobic region (ASY-TTL) results in a different subcellular localization compared to full-length Nogo-B.
The splice variant Nogo-B is expressed in a large variety of tissues in vivo (Chen et al., 2000; Tagami et al., 2000; Li et al., 2001) and in all the cell lines that we examined so far in vitro (COS M7, HEK 293, SH-SY5Y, SK-N-SH, Paju, SaOS-2, 3T3, C2 myoblasts and myotubes, PC12, B104, CG4 and CHO K1; Oertle et al., 2003) . However, there is no apparent correlation between the expression levels of Nogo-B and the tumorigenic properties of the analysed cell lines. The analysis of Genbank data indicates that a variety of cancer cells and tumours express Nogo-B mRNA. In contrast, some tissues do not express Nogo-B, for example, liver and astrocytes (see Figure 2c ; see Northern and Western blots in Tagami et al., 2000; Li et al., 2001; Huber et al., 2002) . These observations speak against the assumption that downregulation of Nogo-B is a general feature of tumorigenesis. In addition, there are a series of studies carried out by the group of Ramaekers and Van de Ven illustrating that the first member of the reticulon family, RTN1, is highly expressed in SCLCs and non-SCLCs. Thus, RTN1 has been suggested as a marker for these tumours (van de Velde et al., 1994b; Senden et al., 1996 Senden et al., , 1997a . The work of Tagami et al. (2000) showed an association and partial colocalization of Nogo-B (Rtn-x S ) with Bcl-2 and Bcl-x L . Moreover, their study shows that both Nogo-B and RTN1-C can interact with Bcl-x L and, in this way, decrease its antiapoptotic effect. Downregulation of Nogo-B mRNA in certain cell types like SCLC might hence reflect a compensatory mechanism between two protein members of the RTN family with overlapping function. In addition, silencing of the Nogo-A/-B promoter (P1) through hypermethylation of its CpGisland could mechanistically account for Nogo-B downregulation in certain cancer cells (Oertle et al., 2003) . The ability of Nogo-B to interact with Bcl-2 proteins, thus interfering with Bcl-2 function, might indicate that the ratio between Nogo-B and Bcl-2 expression is Our data showing that SaOS-2 cells also express endogenous Nogo-B strongly questions the interpretation of the experiments described in earlier reports. Nevertheless, we cannot exclude that SaOS-2 cells used in the different studies underwent genetic drift, thus displaying a dissimilar expression profile.
In contrast to previous studies, we were able to generate stable SaOS-2 cell lines overexpressing different levels of recombinant Nogo-B. These cell lines survive and display no significant alteration in growth rate, and their sensitivity to apoptotic stimuli like staurosporine and tunicamycin is not increased. This is in accordance with the data published by Tagami et al. (2000) , which showed that transient transfection of Nogo-B into the HeLa-derived D98/AH2 cell line does not significantly increase the cells' sensitivity to tunicamycin or staurosporine. However, they could show that Nogo-B was able to reduce the antiapoptotic activity of Bcl-2 and Bcl-x L (Tagami et al., 2000) .
The kinetics of Nogo-B overexpression (stable versus transient) might be essential in the proteins' ability to induce cell death. Differences in experimental set-up (type of cell line, transfection method and plasmid) could also influence the interpretation, particularly since one study observed increased apoptosis of a large variety of cell lines (CGL1, CGL4, SaOS-2, HT1080, MeWo and HFI cells) after transient transfection of Nogo-B even in the absence of apoptotic stimuli (Li et al., 2001) , while in another study the amount of apoptotic cells was not increased after transient transfection into D98 cells (Tagami et al., 2000) .
Interestingly, Nogo-B and RTN1-A, but not RTN3, can significantly reduce the sensitivity of CHO cells to the ER stressor tunicamycin. Since both Nogo-B and RTN1 have been shown to lower the antiapoptotic activity of Bcl proteins, during a stable transfection the cell lines may overcompensate the ER-stress response of RTN1/Nogo-B by overexpression of antiapoptotic proteins or ER chaperones like BiP/ Grp78, or by changing the subcellular localization of proteins like Bcl-2 (Hacki et al., 2000; Annis et al., 2001) .
The characterization of the functional domain of Nogo-B suggested that the second hydrophobic region is important for apoptosis (Li et al., 2001) . Our results show that the second transmembrane region is crucially involved in the ER-membrane association of the Nogo proteins. This suggests an alternative explanation for the significantly higher number of surviving colonies of ASY-TTL transfectants (Li et al., 2001) , that is, reduced ER stress (Herr and Debatin, 2001 ) as compared to fulllength Nogo-B. In another mutant, the exchange of a leucine-zipper-like repeat with two proline residues (ASY-LP; Li et al., 2001) probably disrupts the helical structure of this putative transmembrane domain as has been previously shown for other proteins (see e.g. Nilsson et al., 1998) . The resulting protein is likely to behave similarly to a protein with a deletion of the hydrophobic region. RTN proteins are known to have a high tendency for aggregation, being able to form homo-and heterodimers (Senden et al., 1994) . Overexpression of proteins with such properties, especially also of membrane proteins, can be toxic to cells (Bongarzone et al., 2001) . Endoplasmic reticulum stress can arise from a disturbance in protein folding, leading to an accumulation of un-or misfolded proteins in the organelle (unfolded protein response). The ER can also become saturated when too many proteins are synthesized that need to be processed by the organelle (ERoverload response). Accumulation of proteins in the ER membrane increases its Ca 2+ permeability that could be because of the impairment of Ca 2+ -ATPase function or to an augmented Ca 2+ permeability of the lipid bilayer as a consequence of an increased protein-to-lipid ratio (Pahl, 1999) . Caspase-12, which is specifically localized on the cytoplasmic side of the ER, can be activated by ER stress (Nakagawa et al., 2000) . However, if such a response following ectopic Nogo-B overexpression under a viral CMV promoter is of any physiological relevance is uncertain. This result may be of general importance in the assessment of the proapoptotic function of overexpressed transmembrane or organelle-associated proteins that could lead to aversive cellular reactions due to an organellar-stress response.
In summary, we showed that Nogo-B is endogenously expressed in SaOS-2 cells and that it is possible to stably transfect SaOS-2 cells with Nogo-B. Nogo-B-overexpressing SaOS-2 cells do not significantly differ in proliferation rate or sensitivity to apoptotic stimuli in vitro. If the tumorigenic properties of the stable Nogo-B transfectants are compromised or altered cannot be answered by the present study and would require in vivo experiments.
Our results do not fit with the postulated cancerspecific proapoptotic mechanism and function of Nogo-B, although we cannot exclude its involvement in the development of certain tumours. In our opinion, the function of this protein remains to be elucidated. Most probably, cancer cells do not die because of ASY/Nogo-B.
Materials and methods
Cells
SaOS-2 cells (ACC 243) were obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH) and grown in 85% (v/v) McCoy's MEM (Gibco), 15% (v/v) FCS, at 371C and 5% CO 2 . CHO K1 cells were grown in a-MEM, 5% (v/v) FCS, at 371C and 5% CO 2 . COS M7, HEK 293 and SH-SY5Y cells were grown in DMEM (Gibco), 10% (v/v) FCS, at 371C and 5% CO 2 . Human neuroblastoma cell line SK-N-SH was grown in RPMI 1640, 10% (v/v) FCS at 371C and 5% CO 2 . SH-SY5Y and SK-N-SH were differentiated with retinoic acid.
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EST-database screen
Nogo-B-specific ESTs were screened in the public databases by Blast (Altschul et al., 1997 ) with a nucleotide sequence of 100 bp from nogo exon 1A (50 bp) and exon 4 (50 bp) (Oertle et al., 2003) . Only ESTs overlapping exon 1 and 4 regions were considered as Nogo-B specific.
RT-PCR and cloning
Cells were washed twice with PBS, scraped and centrifuged at 1000 g for 5 min. Poly-A + mRNA was obtained using the Direct Quick Messenger RNA kit (Talent) according to the manufacturer's protocol. cDNA was obtained using Novagen MMLV RT-Polymerase and poly-dT primers from 250 ng mRNA. Of the resulting cDNA, 1/20 was used as a template.
RT-PCR (30 cycles) was performed with transcript-specific forward primers (Nogo-A: 5 0 -GCAGAGCTGAGTAAAACT-TCAG-3 0 ; Nogo-B1: 5 0 -GCAGGGGCTCCGGCTCAGTG-3 0 ; Nogo-B2: 5 0 -GCTCTTCCTGCTGCATCTGAG-3 0 ; Nogo-C: 5 0 -GACAGAAGAAACATTGGAAGG-3 0 ) and the reverse primer located in the conserved region (5 0 -GTTCACATGAC-CAAGAGCAG-3 0 ). PCR products for all transcripts are B300 bp.
PCR (40 cycles) of the C-terminal region of Nogo-B was performed with forward primer 5 0 -GTGTGATCCAAGC-TATCCAG-3 0 and reverse primer 5 0 -CACCAGTGCCTCA-GATAG-3 0 . The PCR product was cloned into pCR4-TOPO (Invitrogen) and transformed into Escherichia coli TOP10 (Invitrogen). The inserts of four clones were sequenced from both sides by Microsynth GmbH and analysed for the presence of mutations using SeqMantII (DnaStar).
Rat RTN1-A (rS-Rex-b) and RTN3 were cloned from a rat cDNA library (Stratagene) and subcloned into pcDNA3.
Antibodies
Generation and characterization of a-Nogo polyclonal AS Bianca (directed against Nogo-A/-B-specific N-terminal region), AS 922 (directed against the C-terminal domain between the two hydrophobic regions, aa 1055-1099 of human Nogo-A), AS Florina (directed against Nogo-A-specific region) and AS 294 (directed against the C-terminal peptide after the second transmembrane domain; KDAMAKIQAKIPGLKR-KAD) have been described elsewhere (Huber et al., 2002; Oertle et al., 2003) .
Rabbit polyclonal a-RTN1-A antiserum was generated by intradermal immunization with prokaryotically expressed and IMAC-purified RTN1 (aa 1-390 of rat RTN1-A).
Mouse a-c-myc mAb (Invitrogen R-950-25), rabbit a-ERK1/ 2 (MAPK) antiserum (Chemicon AB3053) and rabbit a-Bcl-2 antiserum (Oncogene PC68) were purchased.
Western blotting
Western blot was performed as described earlier (Chen et al., 2000; Oertle et al., 2003) . AS 922 was used at a dilution of 1 : 7500 in TBST, 1% (w/v) TopBlockt (Juro Supply, Lucerne), AS 294 and anti-myc mAb were used at a dilution of 1 : 5000, AS Bianca was used at a dilution of 1 : 10 000, AS Florina and a-RTN1-A AS at a dilution of 1 : 20 000, and rabbit a-ERK1/2 (MAPK) and rabbit a-Bcl-2 antisera were used at 0.5 mg/ml. Blots were stripped with Re-Blot (Chemicon) for reprobing. The level of overexpression was determined by densitometry using the NIH Image Program. HRPconjugated goat anti-rabbit and goat anti-mouse (Pierce) at a dilution of 1 : 15 000 were used as secondary antibodies.
Generation of ASY-TTL
ASY-TTL was generated by PCR with Nogo-B-pcDNA3 as template and the primers 5 0 -CTAACTCGAGCGATGGAA-GACATAGACCAG-3 0 and 5 0 -GTGTAAGCTTCAGGGAA-TCAACTAAATCATC-3 0 . The product was cloned into XhoI/ HindIII sites of pcDNA3.1 and sequenced by Microsynth GmbH.
Stable and transient transfection
Nogo-B-pcDNA3 or lacZ-pcDNA3 (1 mg) with 4 ml GeneJuice (Novagen) was used to transfect SaOS-2 cells at 60% confluence. The cells were trypsinized after 48 h and selected with 400 mg/ml G418. Three weeks later, positive colonies were taken, expanded and analysed for Nogo-B-myc expression (with anti-myc mAb). Antibiotic resistant lacZ-pcDNA3 clones were analysed for b-galactosidase expression after 5 min fixation in 2% (w/v) paraformaldehyde (PFA), 0.2% (v/v) glutaraldehyde in PBS, pH 7.3 and stained with 1 mg/ml 5-bromo-4-chloro-3-indolyl-beta-d-galactoside, 2 mm MgCl 2 , 5 mm K 3 Fe(CN) 6 , 5 mm K 4 Fe(CN) 6 in PBS, pH 7.3. Three Nogo-B-positive colonies were subcloned in 96-well plates as single cells and 5 weeks later the growing clones were expanded. Eight independent monoclonal cell lines with different Nogo-B expression levels (strong: B6, B8, D3, D11, E7; medium: C8; weak: C10, D4) were obtained.
1 mg Nogo-B-pcDNA3, RTN1-A-pcDNA3 or RTN3-pcDNA3 with 4 ml FuGENE (Roˆche) were used to stably transfect CHO cells at 40% confluence. The cells were trypsinized after 48 h and selected with 400 mg/ml G418. Resistant colonies were taken and analysed for expression by immunocytochemistry and Western blot using anti-myc mAb as well as RTN1-A-, Nogo-B-and Nogo-A-specific rabbit antisera. Monoclonal cell lines were generated by subcloning in 96-well plates as described above. The Nogo-A CHO cell line was described previously (Chen et al., 2000) .
Nogo-B-pcDNA3 or ASY-TTL-pcDNA3 (1 mg) with 4 ml FuGENE (Roˆche) was used to transiently transfect COS cells at 60% confluence.
Immunocytochemistry
For immunocytochemistry, SaOS-2 or COS cells were grown on glass coverslips and fixed with 4% (w/v) PFA and 5% (w/v) sucrose in PBS for 15 min at RT. Cells were blocked, permeabilized with 0.1% (v/v) Triton-X-100 and incubated with affinity-purified AS 922 (dilution 1 : 50) or mAb anti-myc (dilution 1 : 200) for 1 h. TRITC-conjugated goat anti-rabbit or FITC-conjugated goat anti-mouse (1 : 200; Jackson Immuno Research Laboratories) was added for 30 min at RT.
Determination of cell proliferation rate
SaOS-2 cell lines were plated in six-well dishes at 1 Â 10 4 , 3 Â 10 4 and 6 Â 10 4 cells per dish in the presence or absence of G418. CHO cell lines were plated at a density of 5 Â 10 3 cells per dish. Three squares per dish with defined coordinates were counted each 24 h (CHO cells) or 48 h (SaOS-2 cells).
Apoptosis treatment and determination
CHO and SaOS-2 cell lines were plated at a density of 60% on glass coverslips in four-well dishes for the detection of apoptotic cells and on 10 cm dishes for caspase-3 activity determination. At 48 h after plating, the cells were treated with 1 mm staurosporine (Calbiochem) or 1.8 mm tunicamycin (1.5 mg/ml; Calbiochem) for the indicated time periods.
For the detection of apoptotic cells, samples were fixed for 15 min with 4% (w/v) PFA, 5% (w/v) sucrose in PBS at RT and washed with PBS. DNA fragmentation was detected with Fluorescein-FragELt (cells counterstained with Hoechst) or with TdT-FragELt (Oncogene) according to the manufacturer's protocol.
For the detection of caspase-3 activity, cells were washed with PBS, scraped and centrifuged at 1000 g for 10 min at 41C. Caspase-3 activity was determined using the caspase-3 Cellular Activity Assay Kit (Calbiochem) according to the manufacturer's protocol. The change in optical density (OD 405 ) was measured using an ELISA reader (Multiskan Ascent, Thermo Labsystems, Ascent Software V. 2.4.2). Specific caspase-3 activity per 5 mg cell extract was determined by calculating the slope of the change in OD 405 between 60 and 330 min after the start of measurement and normalized to 30 U recombinant human caspase-3 (positive control).
Cell fractionation
For cell fractionations, 4 mg Nogo-B or ASY-TTL with 16 ml FuGENE (Roˆche) were used to transfect COS cells on 10 cm dishes at 60% confluence. After 48 h, the plates were washed with PBS, scraped and centrifuged at 700 g. Cell pellets of two 10 cm dishes were resuspended in 1 ml ice-cold buffer (50 mm HEPES pH 7.5, 0.25 m sucrose, 100 mm KCl, 5 mm MgAc 2 , Completet (Roˆche) Protease Inhibitors), homogenized with five strokes in a glass-glass Dounce homogenizer, and centrifuged at 41C for 10 min at 12 000 g. Supernatants were centrifuged at 41C for 1 h at 100 000 g in a Beckman ultracentrifuge. The supernatant was taken as cytoplasmic fraction and protein concentration was measured with Advanced Protein Assay Reagent (Cytoskeleton) using BSA as a standard. The pellet was resuspended in 0.5 ml ice-cold Wash buffer (150 mm Tris-HCl pH 8.0, 0.5 m KCl, Completet (Roˆche) Protease Inhibitors) and centrifuged again for 1 h at 100 000 g. Microsomes were resuspended in 80 ml Wash buffer and protein concentration was determined. For Western blotting, 0.5 mg total protein was loaded per lane of a 10% SDS-polyacrylamide gel.
Statistical analysis
Statistical analysis of growth rate, amount of apoptotic cells and caspase-3 activity was performed with SPSS applying an ANOVA for repeated measurement with Greenhouse Geisser Correction.
